ArticleJournal of oncology2011
Phenotypic heterogeneity of breast cancer stem cells.
Article in Journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- Trial
- Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment.Stem cell research & therapy · 2026Review
- Breast Cancer Multicellular Spheroid Models-A Tool for Studying Cancer Biology; a Possible Platform for Drug Screening and Personalized Medicine.International journal of molecular sciences · 2026Review
- The role of telocytes and miR-21-5p in tumorigenicity and metastasis of breast cancer stem cells.Molecular biology reports · 2024Article
- Cancer Stem Cells: Future Possibilities for Cancer Therapy.Indian journal of clinical biochemistry : IJCB · 2023Article
- Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients.Cancer cell international · 2022Article
- CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.International journal of biological sciences · 2022Review
- Signaling pathways governing breast cancer stem cells behavior.Stem cell research & therapy · 2021Review
- The effects of microgravity on differentiation and cell growth in stem cells and cancer stem cells.Stem cells translational medicine · 2020Article
- GPER-induced signaling is essential for the survival of breast cancer stem cells.International journal of cancer · 2020Article
- Cancer stem cell theory: Are we moving past the mist?Journal of the Chinese Medical Association : JCMA · 2019Review
- Metabolism and epigenetics of pancreatic cancer stem cells.Seminars in cancer biology · 2019Review
- CD133 in Breast Cancer Cells: More than a Stem Cell Marker.Journal of oncology · 2019Review
- Nicotine reduces effectiveness of doxorubicin chemotherapy and promotes CD44Experimental and therapeutic medicine · 2018Article
- Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.Diseases (Basel, Switzerland) · 2017Review
- Cancer stem cell targeted therapy: progress amid controversies.Oncotarget · 2015Review
- ALDH1 might influence the metastatic capability of HeLa cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.Antioxidants & redox signaling · 2015Review
- Low spinophilin expression enhances aggressive biological behavior of breast cancer.Oncotarget · 2015Article
- The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model.Oncogene · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many types of tumors are organized in a hierarchy of heterogeneous cell populations, with only a small proportion of cancer stem cells (CSCs) capable of sustaining tumor formation and growth, giving rise to differentiated cells, which form the bulk of the tumor. Proof of the existence of CSC comes from clinical experience with germ-cell cancers, where the elimination of a subset of undifferentiated cells can cure patients (Horwich et al., 2006), and from the study of leukemic cells (Bonnet and Dick, 1997; Lapidot et al., 1994; and Yilmaz et al., 2006). The discovery of CSC in leukemias as well as in many solid malignancies, including breast carcinoma (Al-Hajj et al. 2003; Fang et al., 2005; Hemmati et al., 2003; Kim et al., 2005; Lawson et al., 2007; Li et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2003; and Xin et al., 2005), has suggested a unifying CSC theory of cancer development. The reported general insensitivity of CSC to chemotherapy and radiation treatment (Bao et al., 2006) has suggested that current anticancer drugs, which inhibit bulk replicating cancer cells, may not effectively inhibit CSC. The clinical relevance of targeting CSC-associated genes is supported by several recent studies, including CD44 targeting for treatment of acute myeloid leukemia (Jin et al., 2006), CD24 targeting for treatment of colon and pancreatic cancer (Sagiv et al., 2008), and CD133 targeting for hepatocellular and gastric cancer (Smith et al., 2008). One promising approach is to target CSC survival signaling pathways, where leukemia stem cell research has already made some progress (Mikkola et al., 2010).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.